{
    "success": true,
    "data": {
        "id": 1903209,
        "msgid": "umy-develops-5-ai-prototypes-for-detecting-lymphoma-to-brain-tumours-1785988373",
        "date": "2026-08-06 09:41:48",
        "title": "UMY develops 5 AI prototypes for detecting lymphoma to brain tumours",
        "author": "",
        "source": "ANTARA_ID",
        "tags": "",
        "topic": "Technology",
        "summary": "Universitas Muhammadiyah Yogyakarta (UMY) has developed five artificial intelligence prototypes designed to assist in detecting diseases ranging from malignant lymphoma to brain tumours. The applications, which include LymphoScan and BrainDetect, are intended as support tools rather than replacements for professional medical evaluation. The prototypes have been copyrighted and demonstrated high accuracy in laboratory tests, though researchers stress that clinical and operational impacts must also be considered before real-world deployment.",
        "content": "<p>Universitas Muhammadiyah Yogyakarta (UMY) has developed five\nartificial intelligence (AI) prototypes designed to assist in detecting\nvarious diseases, from malignant lymphoma to brain tumours. UMY\nProfessor of Applied Artificial Intelligence Prof Slamet Riyadi said the\nfive AI-based prototypes include LymphoScan, myStressD, BrainDetect,\nmyHeartD v3, and myDBT-Enhance. \u201cThese applications are designed as\nsupport tools and not as replacements for professional evaluation by\nhealthcare practitioners,\u201d Slamet said while presenting at \u2018The 10th\nInternational Conference on Sustainable Innovation (ICoSI) UMY\u2019 in\nYogyakarta on Wednesday. He said LymphoScan is a web-based application\nthat analyses microscopic images to detect types of malignant lymphoma,\nincluding Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL),\nand Mantle Cell Lymphoma (MCL). Two other prototypes focus on non-cancer\ndetection, namely myStressD for detecting a person\u2019s stress condition\nthrough facial images on mobile devices, and myHeartD v3 which estimates\nthe risk of coronary heart disease from patient questionnaire data.\nSlamet emphasised that all prototypes have been copyrighted and tested\nin the laboratory with high accuracy rates. \u201cA more accurate model does\nnot always mean better service. Its application also depends on speed,\nmemory, and context of use,\u201d he said. According to him, evaluating AI\nmodels in healthcare cannot be measured by a single accuracy metric\nalone, but must also consider operational and clinical impacts before\nbeing applied in daily healthcare services. The UMY research underlying\nthe development of these five prototypes covers four main categories:\nchest and respiratory imaging, cardiovascular and metabolic risk, cancer\nimaging, and mental health and biosignals.<\/p>",
        "url": "https:\/\/jawawa.id\/newsitem\/umy-develops-5-ai-prototypes-for-detecting-lymphoma-to-brain-tumours-1785988373",
        "image": ""
    },
    "sponsor": "Okusi Associates",
    "sponsor_url": "https:\/\/okusiassociates.com"
}